|Bid||10.59 x 900|
|Ask||0.00 x 900|
|Day's Range||10.56 - 11.08|
|52 Week Range||8.65 - 21.64|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals ...
The big shareholder groups in Orchard Therapeutics plc (NASDAQ:ORTX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease theirRead More...
Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ), a rare disease gene therapy company, recently went public, offering 14.29 million shares at $14 each. The shares were listed on the Nasdaq Oct. 31 and ended ...